Copyright Reports & Markets. All rights reserved.

Global and Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Oral Therapy
    • 1.2.3 Injectable Therapy
  • 1.3 Market by Application
    • 1.3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals & Clinics
    • 1.3.3 Home Settings
    • 1.3.4 Ambulatory Surgical Centers (ASCs)
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Growth Trends by Regions
    • 2.2.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Market Size
    • 3.1.1 Global Top Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue
  • 3.4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio
    • 3.4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue in 2019
  • 3.5 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served
  • 3.6 Key Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Solution and Service
  • 3.7 Date of Enter into Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Breakdown Data by Type (2015-2026)

  • 4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Type (2021-2026)

5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Breakdown Data by Application (2015-2026)

  • 5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Historic Market Size by Application (2015-2020)
  • 5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2015-2026)
  • 6.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2015-2020)
  • 6.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2015-2020)
  • 6.4 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2015-2026)
  • 7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2015-2020)
  • 7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2015-2020)
  • 7.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2015-2026)
  • 8.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2015-2020)
  • 8.3 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2015-2020)
  • 8.4 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2015-2026)
  • 9.2 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2015-2020)
  • 9.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2015-2020)
  • 9.4 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size (2015-2026)
  • 10.2 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Astellas Inc.
    • 11.1.1 Astellas Inc. Company Details
    • 11.1.2 Astellas Inc. Business Overview
    • 11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
    • 11.1.4 Astellas Inc. Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2015-2020))
    • 11.1.5 Astellas Inc. Recent Development
  • 11.2 Johnson & Johnson
    • 11.2.1 Johnson & Johnson Company Details
    • 11.2.2 Johnson & Johnson Business Overview
    • 11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
    • 11.2.4 Johnson & Johnson Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2015-2020)
    • 11.2.5 Johnson & Johnson Recent Development
  • 11.3 Sanofi S.A
    • 11.3.1 Sanofi S.A Company Details
    • 11.3.2 Sanofi S.A Business Overview
    • 11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
    • 11.3.4 Sanofi S.A Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2015-2020)
    • 11.3.5 Sanofi S.A Recent Development
  • 11.4 Dendreon Corporation
    • 11.4.1 Dendreon Corporation Company Details
    • 11.4.2 Dendreon Corporation Business Overview
    • 11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
    • 11.4.4 Dendreon Corporation Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2015-2020)
    • 11.4.5 Dendreon Corporation Recent Development
  • 11.5 Bayer AG
    • 11.5.1 Bayer AG Company Details
    • 11.5.2 Bayer AG Business Overview
    • 11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Introduction
    • 11.5.4 Bayer AG Revenue in Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Business (2015-2020)
    • 11.5.5 Bayer AG Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Scope and Market Size
    Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Oral Therapy
    Injectable Therapy

    Market segment by Application, split into
    Hospitals & Clinics
    Home Settings
    Ambulatory Surgical Centers (ASCs)

    Based on regional and country-level analysis, the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Astellas Inc.
    Johnson & Johnson
    Sanofi S.A
    Dendreon Corporation
    Bayer AG
    ...

    Buy now